In contrast, a recent randomized study shows that early administration of CP (within 72 h after the onset of symptoms) with high anti-SARS-CoV-2 levels, significantly reduces the progression to severe respiratory disease [17]. The gene discussed is CP; the disease is respiratory system disorder.